Notably, HER-2 as well as ER/PR were shown to be differentially expressed between the primary tumor and corresponding metastases in up to 48 % which might lead to ineffective treatment in the absence of the respective marker [1–6]. This evidence concerns the gene ESR1 and neoplasm.